KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables - Other: 2021-2025

Historic Receivables - Other for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Sep 2025 value amounting to $21.9 million.

  • Recursion Pharmaceuticals' Receivables - Other rose 298.36% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year increase of 298.36%. This contributed to the annual value of $49.2 million for FY2024, which is 1489.08% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Receivables - Other is $21.9 million, which was up 1.41% from $21.6 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Receivables - Other's 5-year high stood at $49.2 million during Q4 2024, with a 5-year trough of $2.1 million in Q1 2023.
  • Its 3-year average for Receivables - Other is $15.9 million, with a median of $7.5 million in 2024.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Receivables - Other crashed by 81.90% in 2023 and then surged by 1,674.68% in 2025.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Receivables - Other stood at $9.1 million in 2021, then crashed by 69.60% to $2.8 million in 2022, then climbed by 12.39% to $3.1 million in 2023, then surged by 1,489.08% to $49.2 million in 2024, then surged by 298.36% to $21.9 million in 2025.
  • Its last three reported values are $21.9 million in Q3 2025, $21.6 million for Q2 2025, and $46.1 million during Q1 2025.